Galvus generics to be reimbursed despite exclusivity period
By Lee, Tak-Sun | translator Alice Kang
22.02.21 16:34:26
가나다라
0
7 companies including Genuone Sciences to start sales of its generics on March 5th
First generic exclusivity period expired due to substance patent expiry
Ahn-gook unable to enjoy exclusivity in full despite winning the final suit
▲Ahn-gook Pharmaceutical’s that was released 55 days before other generics with generic exclusivity approved by partially invalidating Galvus’s substance patent.
Generic versions of the anti-diabetic DPP-4 inhibitor ‘Galvus (vildagliptin)’ will be released on the 5th of next month in the marketing exclusivity period that is approved for first generics. This is due to the substance patent period of Galvus that will expire the day before. Therefore, Ahn-gook Pharmaceuticals’ marketing exclusivity will also expire in 2 months.
According to industry sources on the 21st, 7 products from 7 companies including Genuone Sciences 'Vildaport tablet 50mg (vildagliptin)’ are preparing to release their products on the 5th of next month.
These are all single-agent drugs containing the main active ingredient vildagliptin. Currently, the sing
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)